Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.790
+0.000 (0.01%)
At close: Jun 26, 2026, 4:00 PM EDT
0.742
-0.048 (-6.08%)
After-hours: Jun 26, 2026, 5:09 PM EDT
Aprea Therapeutics Stock Forecast
APRE's stock price has decreased by -56.11% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Aprea Therapeutics stock have an average target of 4.30, with a low estimate of 1.20 and a high estimate of 6.00. The average target predicts an increase of 444.30% from the current stock price of 0.79.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aprea Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $5 | Buy | Initiates | $5 | +532.91% | Jun 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $1.2 | Buy | Maintains | $1.2 | +51.90% | Jun 1, 2026 |
| Maxim Group | Maxim Group | Buy Reiterates $10 → $5 | Buy | Reiterates | $10 → $5 | +532.91% | May 14, 2026 |
| Wedbush | Wedbush | Buy Reiterates $7 → $6 | Buy | Reiterates | $7 → $6 | +659.49% | May 14, 2026 |
Financial Forecast
Revenue This Year
535.00K
from 285.76K
Increased by 87.22%
Revenue Next Year
1.13M
from 535.00K
Increased by 111.50%
EPS This Year
-0.83
from -1.93
EPS Next Year
-0.79
from -0.83
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.1M | 4.5M | |
| Avg | 535,000 | 1.1M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 648.9% | 746.0% | |
| Avg | 87.2% | 111.5% | |
| Low | -100.0% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.66 | -0.42 | |
| Avg | -0.83 | -0.79 | |
| Low | -0.93 | -1.05 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.